Processa Adds Next-Gen BTK Inhibitor VT-7208, Secures $200M Funding Into 2029 — But Ownership Shifts Dramatically
Processa acquires VT-7208, a next-gen brain-penetrant BTK inhibitor for food allergy, CSU & MS. $200M raise funds trials into 2029.
/ 1 item
#PCSA↓